$88.97
3.15 (-3.41%)
Last updated: Jul 15, 2026 06:58
Fundamentals Overview
Abbott Laboratories is near the low of its 52-week range with moderate valuation, trending downward today.
Valuation moderate
Intrinsic value (DCF)
+64.4% upside vs price
Profitability
Risk (Beta)
0.61 — lower vol
Earnings & growth
BullzEye Analysis
Our composite tilts Hold on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.
Composite Signal
Supporting (Buy):
DCF +64.4% upside vs price · Analyst grade: B · Sentiment improving (1 upgrade)
Pressures (Sell):
3M vs S&P 500: -21.2% · 3M vs Healthcare sector: -18.6%
Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.
Key Stats
About
Ratings & Grades at a Glance
Overall rating: B. Recent institutional grades: majority upgrades. Current institutional positions: Buy: 11, Outperform: 10, Overweight: 9.
Valuation & Ratios
Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.
DCF vs price: DCF estimate is $146.26; current price is $88.97. That’s a +64.4% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.
| Metric | Value |
|---|---|
| Valuation | |
| P/E (TTM) | 24.76 |
| DCF value (model) | $146.26 (64.4% upside) |
| PEG (TTM) | N/A |
| P/B (TTM) | 2.99 |
| P/S (TTM) | 3.43 |
| P/FCF (TTM) | 21 |
| Liquidity & enterprise | |
| Current Ratio (TTM) | 1.39 |
| Quick Ratio (TTM) | 1.01 |
| Cash Ratio (TTM) | 0.37 |
| Profitability | |
| ROE (TTM) | N/A |
| ROA (TTM) | N/A |
| Revenue growth (YoY) | N/A |
| Net margin (TTM) | 13.91% |
| Gross margin (TTM) | 56.38% |
| Operating margin (TTM) | 18.17% |
| Debt to equity (TTM) | N/A |
Latest News
News loads when you open this tab.
Price Target, Ratings & Grades
Analyst price targets, consensus, rating snapshot, and institutional grades for ABT.
Analyst Sentiment at a Glance
Stock Grades (Institutions)
| Institution | Action | Previous Grade | New Grade | Date |
|---|---|---|---|---|
| Evercore ISI Group | maintain | Outperform | Outperform | 2026-07-06 |
| Piper Sandler | maintain | Overweight | Overweight | 2026-06-22 |
| BTIG | maintain | Buy | Buy | 2026-04-27 |
| Barclays | maintain | Overweight | Overweight | 2026-04-20 |
| B of A Securities | maintain | Buy | Buy | 2026-04-17 |
| Piper Sandler | maintain | Overweight | Overweight | 2026-04-17 |
| Benchmark | maintain | Buy | Buy | 2026-04-17 |
| Stifel | maintain | Buy | Buy | 2026-04-17 |
| Evercore ISI Group | maintain | Outperform | Outperform | 2026-04-17 |
| BTIG | maintain | Buy | Buy | 2026-04-17 |
| Oppenheimer | maintain | Outperform | Outperform | 2026-04-17 |
| RBC Capital | maintain | Outperform | Outperform | 2026-04-17 |
| Goldman Sachs | maintain | Buy | Buy | 2026-04-09 |
| Barclays | maintain | Overweight | Overweight | 2026-04-08 |
| Evercore ISI Group | maintain | Outperform | Outperform | 2026-04-06 |
| BTIG | maintain | Buy | Buy | 2026-03-31 |
| Piper Sandler | maintain | Overweight | Overweight | 2026-03-26 |
| Citigroup | maintain | Buy | Buy | 2026-03-11 |
| Barclays | maintain | Overweight | Overweight | 2026-02-02 |
| Freedom Broker | upgrade | Hold | Buy | 2026-01-29 |
| Bernstein | maintain | Outperform | Outperform | 2026-01-23 |
| Evercore ISI Group | maintain | Outperform | Outperform | 2026-01-23 |
| Citigroup | maintain | Buy | Buy | 2026-01-23 |
| Oppenheimer | maintain | Outperform | Outperform | 2026-01-23 |
| Piper Sandler | maintain | Overweight | Overweight | 2026-01-23 |
| BTIG | maintain | Buy | Buy | 2026-01-23 |
| RBC Capital | maintain | Outperform | Outperform | 2026-01-23 |
| Wells Fargo | maintain | Overweight | Overweight | 2026-01-23 |
| Bernstein | maintain | Outperform | Outperform | 2026-01-09 |
| Barclays | maintain | Overweight | Overweight | 2026-01-05 |